Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.
Our most-read content that featured lung cancer included articles on non–small cell lung cancer, how navigation programs can increase screening rates, and a potential link between antidepressants and lung cancer risk.
State of the Science Summit - Lung Cancer: Chaired by Joshua K Sabari, MD
Sandip P. Patel, MD, discusses the exploration of sacituzumab govitecan in the EVOKE-01 and EVOKE-02 trials in NSCLC and expands on future treatment directions with the agent in this patient population.